Recently, the Food & Drug Administration (FDA, USA) has approved the PD-1 inhibitor pembrolizumab with or without cisplatin-based chemotherapy as the first-line therapy for recurrent or metastatic HNSCC [10]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.